FDA Adverse Event Injury Summary report: N

CONTOUR PVA MICROSPHERES

MDR report key: 2433082 · Received January 31, 2012

Report

Report Number
2134265-2012-00107
Event Type
Injury
Date Received
January 31, 2012
Date of Event
October 21, 2011
Report Date
January 6, 2012
Manufacturer
BOSTON SCIENTIFIC - CORK
Product Code
NAJ
PMA / PMN Number
K030966
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
GB
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

DEVICE EVALUATED BY MFR: IT IS INDICATED THAT THE DEVICE WILL NOT BE RETURNED FOR EVALUATION; THEREFORE A FAILURE ANALYSIS OF THE COMPLAINT DEVICE COULD NOT BE COMPLETED. THE BATCH NUMBER IS UNKNOWN AND THE MANUFACTURING RECORDS FOR THE COMPLAINT DEVICE COULD NOT BE REVIEWED. THE ROOT CAUSE IS ANTICIPATED PROCEDURAL COMPLICATIONS AS THIS EVENT IS A KNOWN PHYSIOLOGICAL EFFECT OF THE PROCEDURE AND IS NOTED WITHIN THE DFU. (B)(4).

Description of Event or Problem · 1

SAME CASE AS MDR# 2134265-2012-00042, 2134265-2012-00102, 2134265-2012-00103, 2134265-2012-00104, 2134265-2012-00105, 2134265-2012-00106. IT WAS REPORTED THAT POST A UTERINE FIBROID EMBOLIZATION (UFE) TREATMENT PROCEDURE, SEVERE POST EMBOLIZATION SYNDROME WAS EXPERIENCED. THE PATIENT PRESENTED FOR A UFE PROCEDURE WITH SYMPTOMS OF SWELLING AND BLEEDING. THE PATIENT HAD 30 FIBROIDS. THE PATIENT WAS TREATED ON ONE SIDE USING 3 BOTTLES OF 355 - 500 UM CONTOUR PVA MICROSPHERES. THE OTHER SIDE WAS TREATED USING 3 BOTTLES OF 355 - 500 UM CONTOUR PVA MICROSPHERES AND 1 BOTTLE OF 500-710 UM CONTOUR PVA MICROSPHERES. THERE WAS COMPLETE OCCLUSION OF THE VESSELS AND ALL THE FIBROIDS DIED. FOLLOWING THE PROCEDURE, THE PATIENT CONTINUED TO HAVE AN ELEVATED TEMPERATURE AND INCREASED LEVELS OF LEUKOCYTOSIS AND INFLAMMATORY PROTEINS REQUIRING HOSPITALIZATION FOR ONE MONTH POST PROCEDURE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 CONTOUR PVA MICROSPHERES AGENTS, EMBOLIC, FOR TREATMENT OF UTERINE FIBROIDS NAJ BOSTON SCIENTIFIC - CORK UNK90

Patients

Seq Age Sex Outcome Treatment
1 Hospitalization| O